MedTrace Logo

Prophylactic Anecortave Acetate in Patients With a Retisert Implant

NCT00570479 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-06-05

No results posted yet for this study

Summary

Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA) has been shown to reduce steroid induced elevated IOP. The purpose of this study was to evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to prevent this Retisert induced elevated IOP.

Conditions

Interventions

DRUG

anecortave acetate

Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Texas Retina Associates

    lead OTHER

Principal Investigators

  • David G Callanan, MD · Texas Retina Associates

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570479 on ClinicalTrials.gov